The stock our engine keeps coming back to has a reason

What the system saw

CRNX keeps showing up on our list. That's not noise — that's the point. The Relative Strength Engine flagged it again today, the third entry in seven days, because the stock keeps doing exactly what strong stocks do: pull back just enough to touch support, then stop. Today's low was $84.40. The 20-day moving average is sitting at $83.87. That's not a coincidence — that's the setup. When a name sitting in the 97th percentile for relative strength over the past 63 sessions refuses to break its short-term support, the system pays attention. We're not watching CRNX because it's exciting. We're watching it because it keeps behaving like a well-mannered stock with something to prove.

Why our Relative Strength Engine liked it

A 97th-percentile relative strength ranking means CRNX has outrun roughly 97% of the market over the last three months. The engine doesn't care why — momentum is momentum. What it does care about is whether that strength is cracking, and a clean bounce off the 20-day moving average says it isn't. The reclaim today was tight: just 0.11% off the prior close, with volume drying up on the pullback. Both are textbook signs that sellers aren't showing up with any real conviction. Worth flagging, though: CRNX is a biotech. The fundamentals look rough on the surface — negative earnings, negative ROE, a Piotroski F-Score of 2 out of 9. For a clinical-stage company burning cash to develop drugs, that's not unusual. The Altman Z-Score clocks in at an unusually high 39, which at least says liquidity isn't an immediate concern. Analyst consensus is Buy, with an average price target of $84.86 — essentially where the stock is sitting right now. There's no obvious fundamental tailwind here. The technical setup is doing all the work.

The trade plan

The Relative Strength Engine entered at $84.45. The stop sits at $83.49, just below the 20-day moving average — if that level breaks, the thesis breaks with it. The 2R target is $86.37, which is $1.92 above entry. Risk per share is $0.96. We're putting roughly $5,067 behind this, about 60 shares. A 1:2 risk-to-reward ratio is the floor the engine requires before it pulls the trigger, and this clears it. The trade doesn't need CRNX to do anything dramatic. It just needs to keep holding the level it's already holding and drift toward the target.

Position size: our paper account is putting about $5,067 (60 shares) into this trade, sized to risk roughly $58 if our stop is hit. This is what the system committed in its paper account — not a suggestion of how much you should put into any trade.

What could go wrong

A few things deserve to be said plainly. First, this is a biotech — and biotechs can gap violently on trial data or FDA news with zero warning. No technical level protects against that. Second, we already have two other CRNX positions open, on day 7 and day 2 respectively, which means the system is stacking exposure in one name across multiple entries. That's how the engine is designed to work, not an oversight — but it's real concentration risk, and you should know it's there. Third, the analyst consensus target is only $0.39 above current price. Our system's 2R target of $86.37 actually sits above that consensus, which means Wall Street price targets aren't carrying this trade. It lives or dies on technical behavior.

One more thought before we go

We're 27 days in, and the win rate on closed trades is still zero — all eight closed positions finished in the red. The open book looks better: SNOW, CORT, and two PIII entries are all sitting on solid gains. The system is trailing SPY by 0.8% over that window. None of that changes how CRNX gets evaluated today. The setup either qualifies or it doesn't, and today it did. The real question is whether the open positions convert before the next batch of signals gets added to the pile.